|
Prostaglandin J2 (PGJ2) is an analog of PGD2 that can inhibit both platelet aggregation and cell growth.1,2,3 However, it is not clear whether these effects are initiated by PGJ2 or a derivative. 13,14-dihydro-16,16-difluoro PGJ2 is an analog of PGJ2. While its biological activities have not been evaluated, it should be noted that the addition of two electron-withdrawing fluorine atoms has been used to stabilize prostanoids and significantly delay degradation in vivo.4 Importantly, 13,14-dihydro PGE1 has activity that is comparable to that of PGE1, suggesting that this analog of PGJ2 could be biologically active.5,6
|
|
1
Bundy, G.L., Morton, D.R., Peterson, D.C., et al. Synthesis and platelet aggregation inhibiting activity of prostaglandin D analogues. J Med Chem 26 790-799 (1983).
2
Mahmud, I., Smith, D.L., Whyte, M.A., et al. On the identification and biological properties of prostaglandin J2. Prostaglandins Leukot Med 16 131-146 (1984).
3
Fukushima, M. Prostaglandin J2 - antitumor and anti-viral activities and the mechanisms involved. Eicosanoids 3 189-199 (1990).
4
Hatano, Y., Kohli, J.D., Goldberg, L.I., et al. Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin. Proc Natl Acad Sci USA 77(11) 6846-6850 (1980).
5
Änggård, E. The biological activities of three metabolites of prostaglandin E1. Acta Physiol Scand 66 509-510 (1966).
6
Hamberg, M., Samuelsson, B. On the metabolism of prostaglandins E1 and E2 in man. J Biol Chem 246 6713-6721 (1971).
|